Cost-effectiveness analysis of rezivertinib and gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer
Expert Review of Pharmacoeconomics & Outcomes Research · 2026
DOI: 10.1080/14737167.2026.2626573 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2026. Verfasst von Conghui Kou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Gefitinib, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit nennt 23 Literaturangaben. Gefördert von: the Health Commission of Shandong Province.
Abstract (Originalsprache)
BACKGROUND: Epidermal growth factor receptor (EGFR) mutations represent the primary driver alterations in advanced non-small cell lung cancer (NSCLC). Rezivertinib has emerged as a promising targeted therapy for EGFR-mutated NSCLC. This study aimed to evaluate the cost-effectiveness of rezivertinib versus gefitinib as first-line treatment in Chinese patients with EGFR-mutated advanced NSCLC. RESEARCH DESIGN AND METHODS: A cost-effectiveness analysis was conducted using a 10-year Markov model based on data from the REZOR clinical trial (NCT03866499). Primary outcomes included total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). RESULTS: Rezivertinib demonstrated superior clinical outcomes with a mean QALY of 2.14 compared to 1.79 for gefitinib. However, rezivertinib incurred higher treatment costs ($43390.34 vs $31202.03). The ICER of $35,215.97 per QALY for rezivertinib falls below the willingness-to-pay (WTP) threshold ($40334, three times the per capita GDP), confirming its cost-effectiveness. Sensitivity analysis revealed that rezivertinib had a 71.5% probability of being cost-effective versus 28.5% for gefitinib. Threshold analysis established cost-effective pricing thresholds for rezivertinib ($605.02 at 3×GDP per capita, $408.66 at 1.5×GDP per capita). CONCLUSIONS: Rezivertinib demonstrates significantly better cost-effectiveness compared to gefitinib for first-line treatment of EGFR-mutated advanced NSCLC in China.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan, Shandong, China.
- College of Pharmacy, Shandong Medical College, Jinan, Shandong, China.
ORCID-Profile: Jing Nie
Förderung
- the Health Commission of Shandong Province
Zitieren
APA
Kou, C., Wu, H., Liu, L., Zhao, X., & Nie, J. (2026). Cost-effectiveness analysis of rezivertinib and gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2026.2626573
Vancouver
Kou C, Wu H, Liu L, Zhao X, Nie J. Cost-effectiveness analysis of rezivertinib and gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer. Expert Review of Pharmacoeconomics & Outcomes Research. 2026. doi:10.1080/14737167.2026.2626573
BibTeX
@article{Kou2026,
author = {Kou, Conghui and Wu, Huina and Liu, Lihui and Zhao, Xifeng and Nie, Jing},
title = {Cost-effectiveness analysis of rezivertinib and gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
doi = {10.1080/14737167.2026.2626573}
}
EUVIMED